Increased sales in fourth quarter and full year.

At the beginning of 2022, we were finally able to see the end of the COVID-19 pandemic and have gradually been able to accelerate our activity levels in terms of participation at fairs and congresses and, not least, by being able to have meaningful meetings with our customers. The positive sales trend we have seen during the year continued in the fourth quarter and sales rose by 38 percent to SEK 9.4 (6.8) million. Strengthened by this development, we are now approaching 2023 with great energy and even sharper focus.

• Net sales: SEK 9.4 million (6.8), +38%
• Operating income: SEK -1.8 million (-3.9)
• Net income for the period: SEK -1.9 million (-4.1)
• Earnings per share: SEK -0.03 (-0.06)

• Net sales: SEK 36.1 million (28.2), +28%
• Operating income: SEK -8.3 million (-11.8)
• Net income for the period: SEK -8.6 million (-12.2)
• Earnings per share: SEK -0.12 (-0.17)

• Glycorex attended national transplant congresses in India, Mexico, South Africa, and Germany.
• In South Africa, Glycorex sponsored a symposium in blood group incompatible transplants.
• First order for Glycosorb® ABO from distributor in South Africa.
• First delivery to Mexico since the COVID-19 pandemic.
• New transplant centers were added as customers in India and France.
• Further scientific support for Glycosorb® ABO was presented at the German congress the DTG (der Deutschen Transplantationsgesellschaft).
• The positive development in India continued during the quarter. Of all organ transplants performed with Glycosorb® ABO during 2022 over 20 percent was liver transplants from living donors.
• Excellent results were obtained from the platelet evaluation carried out in the UK.

• Jan 31, 2023: Glycorex strengthens the organization to place additional force behind the growth strategy Going 4 Growth.
• Feb 20, 2023: The first blood group incompatible kidney transplant using Glycosorb ® ABO performed in South Africa.

For more information, please contact

Johan Lavén, CEO Glycorex Transplantation AB
Email: johan.laven@glycorex.com
Tel: + 46 (0)73 330 92 16

This information is the kind of information Glycorex Transplantation AB (publ) is obliged to make public under the EU Market Abuse Act and the Act on the Securities Market. The information was submitted for publication on February 28, 2023, at 08:00 CET.

Brief information about the company

Glycorex Transplantation AB (publ) is a global medical technology company headquartered in Sweden. The company has developed a unique technology to select and remove specific antibodies in the blood.

Glycosorb® ABO is one of the company's self-developed proprietary medical devices that is used to facilitate blood group-incompatible transplants. Whilst primarily used to facilitate blood group incompatible kidney transplants, Glycosorb® ABO is also used in blood group incompatible liver-, heart-, lung-, and stem cell transplants. More than 60 scientific papers have been published in reputable medical journals, showing excellent short- and long-term outcomes of blood group incompatible transplants performed with Glycosorb® ABO. Each kidney transplant saves about 150 dialysis treatments per year. Glycosorb® ABO has been used on five continents in more than 6,000 transplants. In addition to Europe, Glycosorb® ABO is used in Australia, Canada, India, Israel, Mexico, Singapore, South Africa, and Thailand, for example.

The company has also developed a CE-marked medical device product for the production of universal (low titer) blood products and is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis.

Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B